News

4 biomarkers may point to early Parkinson’s disease: Study

A diagnostic panel of four biomarkers that combines the blood levels of a molecule called N-acetylputrescine (NAP) with three clinical features often present in Parkinson’s disease — loss of smell, depression, and acting out dreams — may help identify the disease at its earlier stages, a study found. The…

Companies partner on wearable apomorphine injection system

Serina Therapeutics has partnered with Enable Injections to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced Parkinson’s disease, in combination with the enFuse wearable delivery system. EnFuse is designed to allow patients to self-administer SER-252 subcutaneously (under the skin) in a faster, simpler, and more…

Apomorphine oral spray safe, efficient in Parkinson’s, study finds

An oral spray was safe and efficient at delivering apomorphine to people with Parkinson’s disease, a study found. A subcutaneous injection formulation of apomorphine, sold as Apokyn, is approved in the U.S. to treat off episodes — periods in which symptoms return between doses of levodopa treatment — in…

Targeting specific alpha-synuclein region may thwart toxic aggregation

A region in the alpha-synuclein protein has been identified as a possible target for inhibiting the conversion of oligomers — early aggregates, or clumps, of the protein — into toxic fibrils, a hallmark of Parkinson’s disease, according to a recent study. Mutations in this region are also associated with…

Aspen wins $8M to advance Parkinson’s stem cell therapy

Aspen Neuroscience has been awarded an $8 million grant to advance the clinical development of ANPD001, its investigational stem cell therapy that’s designed to replace dopamine-producing nerve cells lost in Parkinson’s disease. The grant, funded by the California Institute for Regenerative Medicine (CIRM), will support the ongoing Phase…

Early Parkinson’s sleep disorders tied to NfL biomarker in study

The presence of sleep disorders in the earliest stages of Parkinson’s disease correlated with blood levels of neurofilament light chain (NfL), a biomarker of neurodegeneration, in a study. “This finding underscores the potential of sleep disorders as a robust clinical indicator of neuronal degeneration, closely linked with PD [Parkinson’s…